CXL may play role in keratitis


However, more research is needed on the efficacy and safety of this technique

Emerging data suggest a potential role for corneal collagen crosslinking (CXL) in the management of infectious keratitis. Nevertheless, right now there are more questions than answers about the mechanism, efficacy and safety of this technique, said Dr A. John Kanellopoulos, during Cornea Subspecialty Day at the annual meeting of the American Academy of Ophthalmology.

"The findings from these papers are interesting in suggesting that CXL works as a disinfecting and perhaps a sterilizing method within the infected cornea," he said. "That concept is supported by our own experience that includes CXL treatment of a consecutive series of 412 keratoconic eyes without a single infection, although antibiotic prophylaxis was also used. However, for now, ideas about how CXL works in infectious keratitis, modifications to improve its activity, and potential risks are mainly theoretical so that much more research is needed."

Discussing potential mechanisms by which CXL may be an effective treatment for infectious keratitis, Dr Kanellopoulos noted that UVA light with riboflavin is known to have a sterilizing effect. He explained that originally, the photochemical reaction of CXL was attributed to oxygen radical generation (type I) from the interaction of UV light and riboflavin. Recently, an additional mechanism has been theorized involving creation of a riboflavin radical.

"Both the oxygen radicals and possibly energized riboflavin may be directly cytotoxic to microbes," Dr Kanellopoulos said.

A second mechanism, by which CXL might benefit the treatment of infectious keratitis, may be through biomechanical strengthening of the cornea.

"After crosslinking, human corneal tissue has been shown to be much more resistant to enzyme degradation," Dr Kanellopoulos said. "In addition, the procedure may also directly reduce the activity of proteolytic enzymes. Both of these mechanisms may reduce the cornea's susceptibility to infectionrelated melt and the consequent spread of infection within the cornea."

He added that with those latter concepts in mind, he has been performing CXL as a prophylactic treatment in cases of Boston (Dohlman) keratoprosthesis implantation over the past 5 years.

"In these procedures, the vehicle cornea transplanted along with the prosthesis is often susceptible to melts and infectious keratitis due to severe preexisting external disease," Dr Kanellopoulos explained. "With preemptive crosslinking of the vehicle cornea to the prosthesis, we have found a significant reduction of melts and potential infections associated with this very challenging procedure."

He also said that CXL may be helpful in treating infectious keratitis by potentially reducing postinfection scarring, recognizing reports that the crosslinked corneal stroma is denuded of keratocytes for 3 to 6 months. In addition, he presented a case demonstrating how CXL might be used with topographicguided normalization of the cornea as a tool for treating postinfection scarring.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.